Outcomes

The evidence for NAD+ IV drip outcomes is extremely limited, with very few studies directly examining intravenous NAD+ administration and its measurable effects.

Available Evidence:

Only one study specifically addresses intravenous NAD+ infusion - a 2026 retrospective tolerability pilot study comparing IV NAD+ to nicotinamide riboside (NR). This study appears to focus primarily on safety and tolerability rather than efficacy outcomes, though specific results are not detailed in the available abstracts.

A 2026 systematic review examined NAD+ supplementation broadly for anti-aging and wellness applications, but this review covers various forms of NAD+ supplementation (not specifically IV administration) and the specific outcomes reported are not detailed in the available information.

Related NAD+ Research:

Other studies in the literature examine related NAD+ compounds or oral supplementation:

Research on nicotinamide mononucleotide (NMN) showed effects on glucose tolerance and insulin clearance in the context of free fatty acid-induced metabolic changes
Various clinical trials are investigating NAD+ precursors for hematopoietic recovery and vascular aging, but these are either still recruiting participants or have not yet begun

Evidence Limitations:

The current literature provides insufficient evidence to determine specific measurable outcomes from NAD+ IV drip therapy. The available studies do not report concrete biomarker changes, symptom improvements, or other quantifiable results specifically attributable to intravenous NAD+ administration. Most research focuses on tolerability rather than therapeutic efficacy.

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any NAD+ IV therapy.

NAD+ IV Drip

Member access required